Tags

Type your tag names separated by a space and hit enter

Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
Bone Marrow Transplant. 2006 Apr; 37(8):731-7.BM

Abstract

High-dose therapy with autologous stem cell therapy (ASCT) has become the treatment of choice for eligible patients with myeloma. We analysed retrospectively the prognostic influence of pre-transplant characteristics and transplant modalities on response and survival in 211 myeloma patients who were transplanted in our centre between 1994 and 2004. All patients received peripheral blood stem cell support after conditioning with melphalan alone (183 patients), or melphalan and total blood irradiation (28 patients). We evaluated the influence of age, type of multiple myeloma, status prior and post ASCT, previous treatment regimens, time of ASCT from diagnosis, year of autograft, dose of re-infused CD34(+) cells, plasma cell infiltration and beta2-microglobulin at diagnosis on overall survival (OS) and event-free survival (EFS) to define patients with better prognosis. Median OS and EFS from transplantation were 50.9 and 20.1 months, respectively. Median OS from diagnosis was 68.8 months. Transplant-related mortality was 1.4%. Lower beta2-microglobulin levels, achievement of complete remission (CR) post transplant and lower plasma cell infiltration at diagnosis and transplant correlated with longer EFS and OS, whereas CR at transplant and low international prognostic index at transplant correlated with better EFS. Higher CD34(+) cell dose correlated with improved OS. We conclude that ASCT is safe and effective and the outcome is independent of age, time from diagnosis, previous treatment and conditioning regimen.

Authors+Show Affiliations

Department of Haematology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, London, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16501593

Citation

O'Shea, D, et al. "Predictive Factors for Survival in Myeloma Patients Who Undergo Autologous Stem Cell Transplantation: a Single-centre Experience in 211 Patients." Bone Marrow Transplantation, vol. 37, no. 8, 2006, pp. 731-7.
O'Shea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant. 2006;37(8):731-7.
O'Shea, D., Giles, C., Terpos, E., Perz, J., Politou, M., Sana, V., Naresh, K., Lampert, I., Samson, D., Narat, S., Kanfer, E., Olavarria, E., Apperley, J. F., & Rahemtulla, A. (2006). Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplantation, 37(8), 731-7.
O'Shea D, et al. Predictive Factors for Survival in Myeloma Patients Who Undergo Autologous Stem Cell Transplantation: a Single-centre Experience in 211 Patients. Bone Marrow Transplant. 2006;37(8):731-7. PubMed PMID: 16501593.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. AU - O'Shea,D, AU - Giles,C, AU - Terpos,E, AU - Perz,J, AU - Politou,M, AU - Sana,V, AU - Naresh,K, AU - Lampert,I, AU - Samson,D, AU - Narat,S, AU - Kanfer,E, AU - Olavarria,E, AU - Apperley,J F, AU - Rahemtulla,A, PY - 2006/2/28/pubmed PY - 2006/6/13/medline PY - 2006/2/28/entrez SP - 731 EP - 7 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 37 IS - 8 N2 - High-dose therapy with autologous stem cell therapy (ASCT) has become the treatment of choice for eligible patients with myeloma. We analysed retrospectively the prognostic influence of pre-transplant characteristics and transplant modalities on response and survival in 211 myeloma patients who were transplanted in our centre between 1994 and 2004. All patients received peripheral blood stem cell support after conditioning with melphalan alone (183 patients), or melphalan and total blood irradiation (28 patients). We evaluated the influence of age, type of multiple myeloma, status prior and post ASCT, previous treatment regimens, time of ASCT from diagnosis, year of autograft, dose of re-infused CD34(+) cells, plasma cell infiltration and beta2-microglobulin at diagnosis on overall survival (OS) and event-free survival (EFS) to define patients with better prognosis. Median OS and EFS from transplantation were 50.9 and 20.1 months, respectively. Median OS from diagnosis was 68.8 months. Transplant-related mortality was 1.4%. Lower beta2-microglobulin levels, achievement of complete remission (CR) post transplant and lower plasma cell infiltration at diagnosis and transplant correlated with longer EFS and OS, whereas CR at transplant and low international prognostic index at transplant correlated with better EFS. Higher CD34(+) cell dose correlated with improved OS. We conclude that ASCT is safe and effective and the outcome is independent of age, time from diagnosis, previous treatment and conditioning regimen. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/16501593/Predictive_factors_for_survival_in_myeloma_patients_who_undergo_autologous_stem_cell_transplantation:_a_single_centre_experience_in_211_patients_ L2 - https://doi.org/10.1038/sj.bmt.1705307 DB - PRIME DP - Unbound Medicine ER -